SCHEMBL14940258

SCHEMBL14940258

Cc1cc(Br)cc(C)c1Nc1nc(Cl)nc(Cl)n1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 4/20 0.45
HTR1D P28221 1/20 0.42
HTR1B P28222 1/20 0.42
RAPGEF4 Q8WZA2 6/20 0.38
TSHR P16473 1/20 0.38
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 1/20 0.36
APP P05067 1/20 0.36
TXN P10599 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
CRHR1 P34998 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14940191 0.85 RAPGEF4 (0.54) NFKB1RAPGEF4CRHR1
SCHEMBL11639629 0.81 NFKB1 (0.47) NFKB1TSHRMAPTMEN1MAPK1
SCHEMBL14940545 0.81 RAPGEF4 (0.54) NFKB1RAPGEF4APPNPC1POLB
SCHEMBL14939921 0.79 CYP2C9 (0.47) NFKB1RAPGEF4MAPTMEN1MAPK1
SCHEMBL1181589 0.78 NFKB1 (0.53) NFKB1TSHRMAPTMEN1MAPK1
SCHEMBL15266054 0.78 TXN (0.42) NFKB1TSHRMAPTMEN1MAPK1
SCHEMBL11652163 0.77 MAPT (0.47) NFKB1TSHRMAPTMEN1MAPK1
SCHEMBL14939965 0.77 NFKB1 (0.56) NFKB1HTR1DTSHRMAPTMEN1
SCHEMBL3827194 0.69 MAPT (0.40) HTR1DHTR1BMAPTMEN1MAPK1
SCHEMBL11638656 0.68 TSHR (0.47) NFKB1RAPGEF4TSHRMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2828244-B1 TRIAZINES WITH SUITABLE SPACERS FOR TREATMENT AND/OR PREVENTION OF HIV INFECTIONS UNIV ANTWERPEN (BE) 2017-11-15 EP disclosed
EP-2828244-B1 TRIAZINES WITH SUITABLE SPACERS FOR TREATMENT AND/OR PREVENTION OF HIV INFECTIONS UNIV ANTWERPEN (BE) 2017-11-15 EP disclosed
US-9650348-B2 Triazines with suitable spacers for treatment and/or prevention of HIV infections UNIVERSITEIT ANTWERPEN (BE) 2017-05-16 US disclosed
US-9650348-B2 Triazines with suitable spacers for treatment and/or prevention of HIV infections UNIVERSITEIT ANTWERPEN (BE) 2017-05-16 US disclosed
US-9650348-B2 Triazines with suitable spacers for treatment and/or prevention of HIV infections UNIVERSITEIT ANTWERPEN (BE) 2017-05-16 US disclosed
US-20150126510-A1 Triazines With Suitable Spacers for Treatment And/Or Prevention of HIV Infections UNIVERSITEIT ANTWERPEN (BE) 2015-05-07 US disclosed
US-20150126510-A1 Triazines With Suitable Spacers for Treatment And/Or Prevention of HIV Infections UNIVERSITEIT ANTWERPEN (BE) 2015-05-07 US disclosed
US-20150126510-A1 Triazines With Suitable Spacers for Treatment And/Or Prevention of HIV Infections UNIVERSITEIT ANTWERPEN (BE) 2015-05-07 US disclosed
EP-2828244-A1 TRIAZINES WITH SUITABLE SPACERS FOR TREATMENT AND/OR PREVENTION OF HIV INFECTIONS Universiteit Antwerpen (BE) 2015-01-28 EP disclosed
US-20140323488-A1 DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES UNIVERSITEIT ANTWERPEN (BE) 2014-10-30 US disclosed
US-20140323488-A1 DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES UNIVERSITEIT ANTWERPEN (BE) 2014-10-30 US disclosed
EP-2776410-A1 DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES Universiteit Antwerpen (BE) 2014-09-17 EP disclosed
WO-2013139727-A1 TRIAZINES WITH SUITABLE SPACERS FOR TREATMENT AND/OR PREVENTION OF HIV INFECTIONS UNIVERSITEIT ANTWERPEN (BE) 2013-09-26 WO disclosed
WO-2013139727-A1 TRIAZINES WITH SUITABLE SPACERS FOR TREATMENT AND/OR PREVENTION OF HIV INFECTIONS UNIVERSITEIT ANTWERPEN (BE) 2013-09-26 WO disclosed
WO-2013068551-A1 DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES UNIVERSITEIT ANTWERPEN (BE) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323488-A1 DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES TBC1D15, TBC1D5, DHFR NFKB1 559/4885HTR1D 4223/4885HTR1B 3768/4885
US-20150126510-A1 Triazines With Suitable Spacers for Treatment And/Or Prevention of HIV Infections IKZF2, IKZF3, BAZ2A NFKB1 2319/4885HTR1D 3073/4885HTR1B 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.